{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:32:04Z","timestamp":1789129924217,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11764-020-00976-7","type":"journal-article","created":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T11:02:36Z","timestamp":1610794956000},"page":"837-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-1071","authenticated-orcid":false,"given":"Andrea C.","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"issue":"2","key":"976_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/jc.2014-3525","volume":"100","author":"DS Olsson","year":"2015","unstructured":"Olsson DS, Andersson E, Bryngelsson I-L, Nilsson AG, Johannsson G. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab. 2015;100(2):467\u201374. https:\/\/doi.org\/10.1210\/jc.2014-3525.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"976_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/S1478951507070198","volume":"5","author":"S Palmer","year":"2007","unstructured":"Palmer S, Mitchell A, Thompson K, Sexton M. Unmet needs among adolescent cancer patients: a pilot study. Pall Supp Care. 2007;5(2):127\u201334. https:\/\/doi.org\/10.1017\/S1478951507070198.","journal-title":"Pall Supp Care"},{"issue":"2","key":"976_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1634\/theoncologist.2014-0265","volume":"20","author":"SJ Nass","year":"2015","unstructured":"Nass SJ, Beaupin LK, Demark-Wahnefried W, Fasciano K, Ganz PA, Hayes-Lattin B, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine Workshop. Oncologist. 2015;20(2):186\u201395. https:\/\/doi.org\/10.1634\/theoncologist.2014-0265.","journal-title":"Oncologist"},{"issue":"6","key":"976_CR4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.ejca.2008.11.042","volume":"45","author":"G Gatta","year":"2009","unstructured":"Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995\u20132002. Eur J Cancer. 2009;45(6):992\u20131005. https:\/\/doi.org\/10.1016\/j.ejca.2008.11.042.","journal-title":"Eur J Cancer"},{"issue":"2","key":"976_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/jayao.2015.0049","volume":"5","author":"EM Barthel","year":"2016","unstructured":"Barthel EM, Spencer K, Banco D, Kiernan E, Parsons S. Is the adolescent and young adult cancer survivor at risk for late effects? It depends on where you look. J Adolesc Young Adult Oncol. 2016;5(2):159\u201373. https:\/\/doi.org\/10.1089\/jayao.2015.0049.","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"4","key":"976_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220\u201341. https:\/\/doi.org\/10.3322\/caac.21149.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"976_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S1470-2045(18)30941-0","volume":"20","author":"S Gupta","year":"2019","unstructured":"Gupta S. Adolescents and young adults with cancer and the risk of subsequent primary neoplasms: not just big children. Lancet Oncol. 2019;20(4):466\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(18)30941-0.","journal-title":"Lancet Oncol"},{"issue":"14","key":"976_CR8","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1200\/JCO.2009.22.3339","volume":"27","author":"LL Robison","year":"2009","unstructured":"Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute\u2013supported resource for outcome and intervention research. J Clin Oncol. 2009;27(14):2308\u201318. https:\/\/doi.org\/10.1200\/JCO.2009.22.3339.","journal-title":"J Clin Oncol"},{"issue":"15","key":"976_CR9","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cncr.28733","volume":"120","author":"P Youn","year":"2014","unstructured":"Youn P, Milano MT, Constine LS, Travis LB. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer. 2014;120(15):2334\u201342. https:\/\/doi.org\/10.1002\/cncr.28733.","journal-title":"Cancer."},{"issue":"S10","key":"976_CR10","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/cncr.26051","volume":"117","author":"KC Oeffinger","year":"2011","unstructured":"Oeffinger KC, Tonorezos ES. The cancer is over, now what? Cancer. 2011;117(S10):2250\u20137. https:\/\/doi.org\/10.1002\/cncr.26051.","journal-title":"Cancer."},{"key":"976_CR11","unstructured":"Young people\u2019s cancers incidence statistics. Cancer Research UK. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/young-people-cancers\/incidence#ref-2. Published June 12, 2019. Accessed 4 Jan 2020."},{"issue":"16","key":"976_CR12","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1200\/JCO.2011.35.5602","volume":"29","author":"AM Geiger","year":"2011","unstructured":"Geiger AM, Castellino SM. Delineating the age ranges used to define adolescents and young adults. J Clin Oncol. 2011;29(16):e492\u20133. https:\/\/doi.org\/10.1200\/JCO.2011.35.5602.","journal-title":"J Clin Oncol"},{"issue":"7","key":"976_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/cncr.29870","volume":"122","author":"AW Smith","year":"2016","unstructured":"Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, et al. Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Cancer. 2016;122(7):988\u201399. https:\/\/doi.org\/10.1002\/cncr.29870.","journal-title":"Cancer."},{"issue":"2","key":"976_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3747\/co.23.2925","volume":"23","author":"AE Hay","year":"2016","unstructured":"Hay AE, Rae C, Fraser GA, Meyer RM, Abbott LS, Bevan S, et al. Accrual of adolescents and young adults with cancer to clinical trials. Curr Oncol. 2016;23(2):81\u20136. https:\/\/doi.org\/10.3747\/co.23.2925.","journal-title":"Curr Oncol"},{"issue":"2","key":"976_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/pbc.22476","volume":"55","author":"ML McBride","year":"2010","unstructured":"McBride ML, Rogers PC, Sheps SB, et al. Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics. Pediatr Blood Cancer. 2010;55(2):324\u201330. https:\/\/doi.org\/10.1002\/pbc.22476.","journal-title":"Pediatr Blood Cancer"},{"key":"976_CR16","doi-asserted-by":"publisher","unstructured":"Lo AC, Samuel V, Chen B, Savage KJ, Freeman C, Goddard K (2020) Evaluation of the discussion of late effects and screening recommendations in survivors of adolescent and young adult (AYA) lymphoma. https:\/\/doi.org\/10.1007\/s11764-020-00922-7.","DOI":"10.1007\/s11764-020-00922-7"},{"issue":"21","key":"976_CR17","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-06-1420","volume":"12","author":"E Brusamolino","year":"2006","unstructured":"Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin\u2019s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12(21):6487\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1420.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"976_CR18","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/0360-3016(85)90273-1","volume":"11","author":"GW Morgan","year":"1985","unstructured":"Morgan GW, Freeman AP, McLean RG, Jarvie BH, Giles RW. Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin\u2019s disease. Int J Radiat Oncol Biol. 1985;11(11):1925\u201331. https:\/\/doi.org\/10.1016\/0360-3016(85)90273-1.","journal-title":"Int J Radiat Oncol Biol"},{"issue":"32","key":"976_CR19","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1200\/JCO.2010.30.5128","volume":"28","author":"DM Thomas","year":"2010","unstructured":"Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: an emerging field. J Clin Oncol. 2010;28(32):4781\u20132. https:\/\/doi.org\/10.1200\/JCO.2010.30.5128.","journal-title":"J Clin Oncol"},{"issue":"3","key":"976_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/cncr.11095","volume":"97","author":"JG Gurney","year":"2003","unstructured":"Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97(3):663\u201373. https:\/\/doi.org\/10.1002\/cncr.11095.","journal-title":"Cancer."},{"issue":"1","key":"976_CR21","doi-asserted-by":"publisher","first-page":"e2018020","DOI":"10.4084\/mjhid.2018.020","volume":"10","author":"P Angelini","year":"2017","unstructured":"Angelini P, Rodriguez L, Zolaly M, Naqvi A, Weitzman S, Abla O, et al. Outcome and toxicity patterns in children and adolescents with non-Hodgkin lymphoma: a single institution experience. Mediterr J Hematol Infect Dis. 2017;10(1):e2018020\u20138. https:\/\/doi.org\/10.4084\/mjhid.2018.020.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"976_CR22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","volume":"17","author":"N Bhakta","year":"2016","unstructured":"Bhakta N, Liu Q, Yeo F, Baassiri M, Ehrhardt MJ, Srivastava DK, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016;17(9):1325\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(16)30215-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"976_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.5301\/tj.5000670","volume":"103","author":"C Materazzo","year":"2017","unstructured":"Materazzo C, Massimino M, Schiavello E, Podda M, Gandola L, Cefalo G, et al. Clinical and subclinical cardiac late effects in pediatric Hodgkin\u2019s lymphoma survivors. Tumori J. 2017;103(6):566\u201371. https:\/\/doi.org\/10.5301\/tj.5000670.","journal-title":"Tumori J"},{"issue":"4","key":"976_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1097-0142(19840215)53:4<878::aid-cncr2820530411>3.0.co;2-j","volume":"53","author":"LS Constine","year":"1984","unstructured":"Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS. Thyroid dysfunction after radiotherapy in children with Hodgkin\u2019s disease. Cancer. 1984;53(4):878\u201383. https:\/\/doi.org\/10.1002\/1097-0142(19840215)53:4<878::aid-cncr2820530411>3.0.co;2-j.","journal-title":"Cancer."},{"issue":"24","key":"976_CR25","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa022628","volume":"348","author":"BMP Aleman","year":"2003","unstructured":"Aleman BMP, Raemaekers JMM, Tirelli U, Bortolus R, van 't Veer M, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2003;348(24):2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa022628.","journal-title":"N Engl J Med"},{"issue":"8","key":"976_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jnci\/93.8.618","volume":"93","author":"JP Neglia","year":"2001","unstructured":"Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618\u201329. https:\/\/doi.org\/10.1093\/jnci\/93.8.618.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"976_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1210\/jc.2006-0020","volume":"91","author":"W Chemaitilly","year":"2006","unstructured":"Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723\u20138. https:\/\/doi.org\/10.1210\/jc.2006-0020.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"976_CR28","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/cncr.10978","volume":"95","author":"AC Mertens","year":"2002","unstructured":"Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary complications in survivors of childhood and adolescent cancer. Cancer. 2002;95(11):2431\u201341. https:\/\/doi.org\/10.1002\/cncr.10978.","journal-title":"Cancer."},{"issue":"5","key":"976_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","volume":"98","author":"E Hahn","year":"2017","unstructured":"Hahn E, Jiang H, Ng A, Bashir S, Ahmed S. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol. 2017;98(5):1116\u201323. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.03.026.","journal-title":"Int J Radiat Oncol Biol"},{"issue":"5","key":"976_CR30","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","volume":"109","author":"BMP Aleman","year":"2007","unstructured":"Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878\u201386. https:\/\/doi.org\/10.1182\/blood-2006-07-034405.","journal-title":"Blood."},{"issue":"32","key":"976_CR31","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1200\/JCO.2009.23.4278","volume":"28","author":"DR Freyer","year":"2010","unstructured":"Freyer DR. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol. 2010;28(32):4810\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.4278.","journal-title":"J Clin Oncol"},{"issue":"11","key":"976_CR32","doi-asserted-by":"publisher","first-page":"e26587","DOI":"10.1002\/pbc.26587","volume":"64","author":"KT Sadak","year":"2017","unstructured":"Sadak KT, Neglia JP, Freyer DR, Harwood E. Identifying metrics of success for transitional care practices in childhood cancer survivorship: a qualitative study of survivorship providers. Pediatr Blood Cancer. 2017;64(11):e26587. https:\/\/doi.org\/10.1002\/pbc.26587.","journal-title":"Pediatr Blood Cancer"},{"key":"976_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/eje.0.1430639","volume":"143","author":"T Bj\u00f8ro","year":"2000","unstructured":"Bj\u00f8ro T, Holman J, Kr\u00fcger \u00d8, Midthjell K. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Tr\u00f9ndelag (HUNT). Eur J Endocrinol. 2000;143:639\u201347.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"976_CR34","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ijc.24147","volume":"124","author":"A Andersson","year":"2009","unstructured":"Andersson A, N\u00e4slund U, Tavelin B, Enblad G, Gustavsson A, Malmer B. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors-retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124(8):1914\u20137. https:\/\/doi.org\/10.1002\/ijc.24147.","journal-title":"Int J Cancer"},{"issue":"8","key":"976_CR35","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1503\/cmaj.091676","volume":"182","author":"M Chiu","year":"2010","unstructured":"Chiu M, Austin PC, Manuel DG, Tu JV. Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. Can Med Assoc J. 2010;182(8):E301\u201310. https:\/\/doi.org\/10.1503\/cmaj.091676.","journal-title":"Can Med Assoc J"},{"issue":"6","key":"976_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/02841868409136039","volume":"23","author":"L Cionini","year":"1984","unstructured":"Cionini L, Pacini P, De Paola E, et al. Respiratory function tests after mantle irradiation in patients with Hodgkin\u2019s disease. Acta Radiol Oncol. 1984;23(6):401\u20139. https:\/\/doi.org\/10.3109\/02841868409136039.","journal-title":"Acta Radiol Oncol"},{"issue":"3","key":"976_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/07357909909021418","volume":"17","author":"E Salloum","year":"1999","unstructured":"Salloum E, Tanoue LT, Wackers FJ, Zelterman D, Hu GL, Cooper DL. Assessment of cardiac and pulmonary function in adult patients with Hodgkin\u2019s disease treated with ABVD or MOPP\/ABVD plus adjuvant low-dose mediastinal irradiation. Cancer Investig. 1999;17(3):171\u201380. https:\/\/doi.org\/10.3109\/07357909909021418.","journal-title":"Cancer Investig"},{"issue":"1","key":"976_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0360-3016(89)90013-8","volume":"16","author":"LM Smith","year":"1989","unstructured":"Smith LM, Mendenhall NP, Cicale MJ, Block ER, Carter RL, Million RR. Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol. 1989;16(1):79\u201384. https:\/\/doi.org\/10.1016\/0360-3016(89)90013-8.","journal-title":"Int J Radiat Oncol Biol"},{"issue":"3","key":"976_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0360-3016(90)90500-j","volume":"19","author":"SJ Shapiro","year":"1990","unstructured":"Shapiro SJ, Shapiro SD, Mill WB, Campbell EJ. Prospective study of long-term pulmonary manifestations of mantle irradiation. Int J Radiat Oncol Biol. 1990;19(3):707\u201314. https:\/\/doi.org\/10.1016\/0360-3016(90)90500-j.","journal-title":"Int J Radiat Oncol Biol"},{"issue":"1","key":"976_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00000421-200002000-00004","volume":"23","author":"F Villani","year":"2000","unstructured":"Villani F, Viviani S, Bonfante V, De Maria P, Soncini F, Laffranchi A. Late pulmonary effects in favorable stage I and IIA Hodgkin\u2019s disease treated with radiotherapy alone. Am J Clin Oncol. 2000;23(1):18\u201321. https:\/\/doi.org\/10.1097\/00000421-200002000-00004.","journal-title":"Am J Clin Oncol"},{"issue":"6D","key":"976_CR41","first-page":"4739","volume":"17","author":"F Villani","year":"1997","unstructured":"Villani F, De Maria P, Bonfante V, et al. Late pulmonary toxicity after treatment for Hodgkin\u2019s disease. Anticancer Res. 1997;17(6D):4739\u201342.","journal-title":"Anticancer Res"},{"issue":"3","key":"976_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0959-8049(93)90382-p","volume":"29A","author":"EA Hassink","year":"1993","unstructured":"Hassink EA, Souren TS, Boersma LJ, et al. Pulmonary morbidity 10-18 years after irradiation for Hodgkin\u2019s disease. Eur J Cancer. 1993;29A(3):343\u20137. https:\/\/doi.org\/10.1016\/0959-8049(93)90382-p.","journal-title":"Eur J Cancer"},{"issue":"5","key":"976_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a059221","volume":"6","author":"MB Lund","year":"1995","unstructured":"Lund MB, Kongerud J, Nome O, Abrahamsen AF, Bj\u03c0rtuft \u00d8, Forfang K, et al. Lung function impairment in long-term survivors of Hodgkin\u2019s disease. Ann Oncol. 1995;6(5):495\u2013501. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a059221.","journal-title":"Ann Oncol"},{"issue":"12","key":"976_CR44","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1002\/1097-0142(19930615)71:12<4084::AID-CNCR2820711246>3.0.CO;2-B","volume":"71","author":"JDI Ellenhorn","year":"1993","unstructured":"Ellenhorn JDI, Lambroza A, Lindsley KL, Laquaglia MP. Treatment-related esophageal stricture in pediatric patients with cancer. Cancer. 1993;71(12):4084\u201390. https:\/\/doi.org\/10.1002\/1097-0142(19930615)71:12<4084::AID-CNCR2820711246>3.0.CO;2-B.","journal-title":"Cancer."},{"issue":"1","key":"976_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s003300050123","volume":"7","author":"S Mahboubi","year":"1997","unstructured":"Mahboubi S, Silber JH. Radiation-induced esophageal strictures in children with cancer. Eur Radiol. 1997;7(1):119\u201322. https:\/\/doi.org\/10.1007\/s003300050123.","journal-title":"Eur Radiol"},{"key":"976_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.archoralbio.2016.08.023","volume":"72","author":"L Marangoni-Lopes","year":"2016","unstructured":"Marangoni-Lopes L, Rodrigues LP, Mendonca RH, Nobre-dos SM. Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease. Arch Oral Biol. 2016;72:99\u2013105. https:\/\/doi.org\/10.1016\/j.archoralbio.2016.08.023.","journal-title":"Arch Oral Biol"},{"issue":"2","key":"976_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/COC.0b013e3181841f42","volume":"32","author":"DT Chang","year":"2009","unstructured":"Chang DT, Amdur RJ, Pacholke H, Mendenhall NP, Morris CG, Byer GA, et al. Xerostomia in long-term survivors of aggressive non-Hodgkin\u2019s lymphoma of Waldeyer\u2019s ring: a potential role for parotid-sparing techniques? Am J Clin Oncol. 2009;32(2):145\u20139. https:\/\/doi.org\/10.1097\/COC.0b013e3181841f42.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"976_CR48","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ijrobp.2008.12.053","volume":"75","author":"NA Rodrigues","year":"2009","unstructured":"Rodrigues NA, Killion L, Hickey G, Silver B, Martin C, Stevenson MA, et al. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. Int J Radiat Oncol Biol. 2009;75(4):1079\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.12.053.","journal-title":"Int J Radiat Oncol Biol."},{"issue":"1","key":"976_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1748-717X-2-13","volume":"2","author":"E-S Koh","year":"2007","unstructured":"Koh E-S, Tran T, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin\u2019s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2(1):13\u20131. https:\/\/doi.org\/10.1186\/1748-717X-2-13.","journal-title":"Radiat Oncol"},{"issue":"8","key":"976_CR50","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","volume":"24","author":"MV Maraldo","year":"2013","unstructured":"Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosensch\u00f6ld P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdt156.","journal-title":"Ann Oncol"},{"issue":"5","key":"976_CR51","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/annonc\/mdr439","volume":"23","author":"BA Campbell","year":"2012","unstructured":"Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2012;23(5):1259\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdr439.","journal-title":"Ann Oncol"},{"issue":"4","key":"976_CR52","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/pbc.24861","volume":"61","author":"MV Maraldo","year":"2013","unstructured":"Maraldo MV, J\u00f8rgensen M, Brodin NP, Aznar MC, Vogelius IR, Petersen PM, et al. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer. 2013;61(4):717\u201322. https:\/\/doi.org\/10.1002\/pbc.24861.","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"976_CR53","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","volume":"27","author":"ML De Bruin","year":"2009","unstructured":"De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239\u201346. https:\/\/doi.org\/10.1200\/JCO.2008.19.9174.","journal-title":"J Clin Oncol"},{"issue":"12","key":"976_CR54","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","volume":"17","author":"J Franklin","year":"2006","unstructured":"Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin\u2019s lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17(12):1749\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdl302.","journal-title":"Ann Oncol"},{"issue":"6","key":"976_CR55","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3816\/CLM.2006.n.026","volume":"6","author":"A Draube","year":"2011","unstructured":"Draube A, Behringer K, Diehl V. German Hodgkin\u2019s Lymphoma Study Group trials: lessons from the past and current strategies. Clin Lymphoma Myeloma. 2011;6(6):458\u201368. https:\/\/doi.org\/10.3816\/CLM.2006.n.026.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"976_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2017","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2017;68(2):116\u201332. https:\/\/doi.org\/10.3322\/caac.21438.","journal-title":"CA Cancer J Clin"},{"key":"976_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijrobp.2016.01.053","volume":"95","author":"R Zhou","year":"2016","unstructured":"Zhou R, Ng A, Constine LS, Stovall M, Armstrong GT, Neglia JP, et al. A comparative evaluation of Normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the childhood Cancer Survivor Study and Recent Children\u2019s Oncology Group Trials. Int J Radiat Oncol Biol. 2016;95:1\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.01.053.","journal-title":"Int J Radiat Oncol Biol"},{"issue":"1","key":"976_CR58","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/HS9.0000000000000007","volume":"1","author":"SM Ansell","year":"2017","unstructured":"Ansell SM. Maintaining efficacy but decreasing toxicity in the treatment of Hodgkin lymphoma. HemaSphere. 2017;1(1):e7\u20132. https:\/\/doi.org\/10.1097\/HS9.0000000000000007.","journal-title":"HemaSphere."},{"key":"976_CR59","unstructured":"Children\u2019s Oncology Group: long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 5.0. 2018:1\u2013232. http:\/\/www.survivorshipguidelines.org\/. Accessed 01 Sep 2020."}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-020-00976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-020-00976-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-020-00976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T13:10:26Z","timestamp":1634303426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-020-00976-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1007\/s11764-020-00976-7","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,16]]},"assertion":[{"value":"7 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.J.S received institutional research funding from Roche. C.F. has honoraria from Seattle Genetics, Janssen, Amgen, Celgene and Abbvie, and research funding from Roche and Teva. None of the other authors have conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the University of BC \/ BC Cancer Research Ethics Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}